Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics
AUPH Price/Volume Stats
| Current price | $5.09 | 52-week high | $12.43 |
| Prev. close | $5.05 | 52-week low | $4.71 |
| Day low | $5.02 | Volume | 625,241 |
| Day high | $5.16 | Avg. volume | 2,175,463 |
| 50-day MA | $5.47 | Dividend yield | N/A |
| 200-day MA | $7.97 | Market Cap | 736.11M |
AUPH Stock Price Chart Interactive Chart >
Aurinia Pharmaceuticals Inc (AUPH) Company Bio
Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.
Latest AUPH News From Around the Web
Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year. |
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200ROCKVILLE, Md. & EDMONTON, Alberta, December 20, 2023--Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 |
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey MedicalAurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article. |
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New YearInnovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio. |
This Small Pharma Could Be Targeted, But Would Be Fine Alone, TooAt the end of November, AbbVie bought ImmunoGen, Inc. for $10 billion in cash. The purchase of ImmunoGen caused that stock to soar some 90%. Back to the covered call idea on a small biopharma Aurinia Pharmaceuticals, which currently trades just under nine bucks a share. |
AUPH Price Returns
| 1-mo | 2.41% |
| 3-mo | -35.41% |
| 6-mo | -30.56% |
| 1-year | -52.65% |
| 3-year | -59.25% |
| 5-year | -17.64% |
| YTD | -43.38% |
| 2023 | 108.10% |
| 2022 | -81.11% |
| 2021 | 65.37% |
| 2020 | -31.74% |
| 2019 | 197.07% |
Continue Researching AUPH
Here are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...